Impact of type 2-targeted therapies on respiratory infection risk
puremagic
1小时前
40
10
已完结
1. 当前求助状态已完结, 请及时下载应助文件
2. 系统将在 2026-02-12 12:50:39 删除文件
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接:
其他信息:
K Smiley, N Zuhdi, B Geng
Current Opinion in Allergy and …, 2026
journals.lww.com
T2-modulating biologics not only control allergic inflammation but also restore epithelial and immune homeostasis, contributing to maintained or reduced respiratory infection risk. These therapies represent a dual benefit of barrier repair and immune rebalancing. Further studies are warranted to evaluate long-term infection outcomes in high-risk populations.
